Chronic Lymphocytic Leukemia | Specialty

Immunotherapy in Hematologic Malignancies

June 24th 2015

Expanded Idelalisib Indication in CLL on Horizon After Positive Phase III Combo Trial With Ofatumumab

June 24th 2015

OncLive spoke with Jeffrey Jones, MD, MPH, to better understand the Study 119 results, as well as the role idelalisib and other novel targeted agents will play in CLL going forward.

HELIOS Ibrutinib Data 'Practice Changing' for CLL, Says Chanan-Khan

June 23rd 2015

Lead author Asher A. Chanan-Khan, MD, discusses the HELIOS trial, in which adding ibrutinib to bendamustine and rituximab lowered the risk of disease progression by 80% in patients with CLL.

Dr. Chanan-Khan Discusses Ibrutinib and BR in CLL

June 23rd 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses ibrutinib (Imbruvica) combined with rituximab and bendamustine (BR) as treatment of chronic lymphocytic leukemia (CLL) from a mechanism of action point of view.

Martin Barrett on Intravenous Versus Subcutaneous Rituximab

June 20th 2015

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Dr. Atanasio on Ibrutinib and Obinuzutumab Combination in CLL/SLL

June 20th 2015

Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Dr. Wiestner Discusses Findings From the Phase III HELIOS Trial

June 19th 2015

Adrian Wiestner, MD, PhD, National Institutes of Health, National Heart, Lung, and Blood Services, discusses findings from the phase III HELIOS trial, which explored the addition of ibrutinib to bendamustine and rituximab for patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. O'Brien Discusses Ibrutinib and Idelalisib in CLL

June 19th 2015

Susan M. O'Brien, MD, associate director, Clinical Science Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, Chao Family Comprehensive Cancer Center, University of California at Irvine, discusses the use of ibrutinib and idealisib in chronic lymphocytic leukemia (CLL).

2015 EHA Congress Highlights

June 18th 2015

Ofatumumab/Chemo Combo Improves PFS By Over 50% in CLL

June 12th 2015

Adding ofatumumab to fludarabine and cyclophosphamide reduced the risk of disease progression by 54% in patients with relapsed chronic lymphocytic leukemia.

Dr. Jeffrey Jones on Efficacy of Idelalisib/Ofatumumab Combination in CLL

May 31st 2015

Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses the results of a phase III randomized, controlled study evaluating idelalisib (Zydelig) in combination with ofatumumab (Arzerra) compared to ofatumumab alone for previously treated CLL.

Dr. Chanan-Khan on Ibruitinib Combined with BR in CLL/SLL

May 30th 2015

Asher A. Chanan-Khan, MD, chair, Hematology/Oncology, Cancer Center, Mayo Clinic, discusses a recent study that examined ibrutinib combined with bendamustine and ritxuimab (BR) in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Ibrutinib Regimen Improves PFS by 80% in Phase III CLL Study

May 30th 2015

Adding ibrutinib to standard bendamustine and rituximab (BR) reduced the risk of disease progression by 80% compared with BR plus placebo in patients with pretreated CLL or SLL.

Deletion 20q in CLL May Represent Disease Progression

May 28th 2015

The identification of a deletion 20q in a patient with chronic lymphocytic leukemia may not indicate they have developed a myelodysplastic syndrome as was previously assumed.

Dr. Wierda on Ibrutinib Resistance in CLL

May 26th 2015

William G. Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses resistance to ibrutinib in patients with chronic lymphocytic leukemia (CLL).

Novel BTK Inhibitors and Combos May Hold the Key to B-Cell Malignancies

May 21st 2015

Combination therapy has significant potential to fill the niche of developing resistance to BTK inhibitors and rational pairings of ibrutinib with other standard treatments, including chemoimmunotherapy and CD20-targeting monoclonal antibodies (mAbs) are rapidly gaining ground.

Siteman Cancer Center Houses Broad Research Program

May 15th 2015

Venetoclax Breakthrough Designation, Zarxio Legal Update, and More

May 15th 2015

Dr. Lamanna on Incorporating Novel and Traditional Therapies in CLL

May 15th 2015

Nicole Lamanna, MD, Associate Professor of Clinical Medicine, Columbia University Medical Center, discusses incorporating novel therapies into the standard treatment paradigm for patients with chronic lymphocytic leukemia (CLL).

FDA Grants Venetoclax Breakthrough Designation for CLL

May 7th 2015

The FDA has granted a breakthrough therapy designation to the Bcl-2 inhibitor venetoclax (GDC-0199/ABT-199) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia who harbor a 17p deletion (del[17p]).